Chlorine in PDB 8gz6: Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain
Protein crystallography data
The structure of Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain, PDB code: 8gz6
was solved by
K.Yamaguchi,
I.Anzai,
R.Maeda,
M.Moriguchi,
T.Watanabe,
A.Imura,
A.Takaori-Kondo,
T.Inoue,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Resolution Low / High (Å)
|
42.18 /
1.35
|
Space group
|
P 1 21 1
|
Cell size a, b, c (Å), α, β, γ (°)
|
39.758,
32.113,
84.566,
90,
93.96,
90
|
R / Rfree (%)
|
14.9 /
18
|
Chlorine Binding Sites:
The binding sites of Chlorine atom in the Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain
(pdb code 8gz6). This binding sites where shown within
5.0 Angstroms radius around Chlorine atom.
In total 4 binding sites of Chlorine where determined in the
Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain, PDB code: 8gz6:
Jump to Chlorine binding site number:
1;
2;
3;
4;
Chlorine binding site 1 out
of 4 in 8gz6
Go back to
Chlorine Binding Sites List in 8gz6
Chlorine binding site 1 out
of 4 in the Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 1 of Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Cl501
b:19.6
occ:1.00
|
O
|
A:HOH708
|
3.1
|
37.2
|
1.0
|
N
|
A:ASN33
|
3.2
|
15.6
|
1.0
|
N
|
A:GLY100
|
3.4
|
15.7
|
1.0
|
CA
|
A:GLY99
|
3.6
|
14.4
|
1.0
|
ND2
|
A:ASN33
|
3.7
|
15.7
|
1.0
|
CG
|
A:ASN33
|
3.7
|
14.4
|
1.0
|
CB
|
A:ASN33
|
3.8
|
14.3
|
1.0
|
CA
|
A:TYR32
|
3.8
|
16.8
|
1.0
|
CD1
|
A:TYR32
|
3.9
|
23.9
|
1.0
|
C
|
A:GLY99
|
3.9
|
15.0
|
1.0
|
O
|
A:GLY100
|
4.0
|
15.9
|
1.0
|
C
|
A:TYR32
|
4.0
|
16.0
|
1.0
|
CA
|
A:ASN33
|
4.0
|
14.2
|
1.0
|
N
|
A:GLY99
|
4.1
|
14.8
|
1.0
|
CB
|
A:TYR32
|
4.2
|
18.7
|
1.0
|
OD1
|
A:ASN33
|
4.2
|
16.3
|
1.0
|
O
|
A:ASN33
|
4.4
|
14.7
|
1.0
|
CA
|
A:GLY100
|
4.5
|
15.7
|
1.0
|
CG
|
A:TYR32
|
4.5
|
21.1
|
1.0
|
C
|
A:GLY100
|
4.6
|
15.1
|
1.0
|
C
|
A:ASN33
|
4.7
|
13.1
|
1.0
|
O
|
A:VAL31
|
4.9
|
25.4
|
1.0
|
CE1
|
A:TYR32
|
4.9
|
26.8
|
1.0
|
|
Chlorine binding site 2 out
of 4 in 8gz6
Go back to
Chlorine Binding Sites List in 8gz6
Chlorine binding site 2 out
of 4 in the Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 2 of Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
A:Cl502
b:19.2
occ:1.00
|
O
|
A:HOH692
|
3.0
|
44.5
|
1.0
|
NH1
|
A:ARG105
|
3.2
|
17.7
|
1.0
|
N
|
A:ARG45
|
3.2
|
17.4
|
1.0
|
CG
|
A:ARG45
|
3.7
|
19.7
|
1.0
|
CB
|
A:ARG45
|
3.7
|
18.4
|
1.0
|
CD
|
A:ARG105
|
3.8
|
17.0
|
1.0
|
CA
|
A:GLU44
|
3.9
|
21.9
|
1.0
|
C
|
A:GLU44
|
4.1
|
20.2
|
1.0
|
CB
|
A:GLU44
|
4.1
|
25.5
|
1.0
|
CA
|
A:ARG45
|
4.1
|
17.8
|
1.0
|
CD
|
A:ARG45
|
4.1
|
21.3
|
1.0
|
NE2
|
A:GLN39
|
4.2
|
20.8
|
1.0
|
CZ
|
A:ARG105
|
4.3
|
16.4
|
1.0
|
CG
|
A:GLU44
|
4.4
|
32.1
|
1.0
|
NE
|
A:ARG45
|
4.5
|
21.6
|
1.0
|
NE
|
A:ARG105
|
4.5
|
16.8
|
1.0
|
O
|
A:ARG45
|
4.7
|
20.7
|
1.0
|
C
|
A:ARG45
|
4.9
|
17.6
|
1.0
|
CD
|
A:GLN39
|
5.0
|
19.4
|
1.0
|
|
Chlorine binding site 3 out
of 4 in 8gz6
Go back to
Chlorine Binding Sites List in 8gz6
Chlorine binding site 3 out
of 4 in the Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 3 of Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:Cl501
b:20.2
occ:1.00
|
N
|
B:ASN33
|
3.2
|
16.2
|
1.0
|
N
|
B:GLY100
|
3.4
|
16.4
|
1.0
|
CA
|
B:GLY99
|
3.6
|
16.4
|
1.0
|
ND2
|
B:ASN33
|
3.7
|
16.7
|
1.0
|
CG
|
B:ASN33
|
3.7
|
15.0
|
1.0
|
CB
|
B:ASN33
|
3.8
|
15.2
|
1.0
|
CA
|
B:TYR32
|
3.8
|
18.4
|
1.0
|
C
|
B:GLY99
|
3.9
|
17.5
|
1.0
|
O
|
B:GLY100
|
4.0
|
17.3
|
1.0
|
C
|
B:TYR32
|
4.0
|
18.0
|
1.0
|
CD1
|
B:TYR32
|
4.0
|
24.2
|
1.0
|
N
|
B:GLY99
|
4.1
|
15.4
|
1.0
|
CA
|
B:ASN33
|
4.1
|
14.8
|
1.0
|
OD1
|
B:ASN33
|
4.3
|
17.6
|
1.0
|
CB
|
B:TYR32
|
4.3
|
19.6
|
1.0
|
O
|
B:ASN33
|
4.4
|
16.4
|
1.0
|
CA
|
B:GLY100
|
4.5
|
17.8
|
1.0
|
C
|
B:GLY100
|
4.6
|
16.6
|
1.0
|
O
|
B:VAL31
|
4.7
|
23.9
|
1.0
|
CG
|
B:TYR32
|
4.7
|
22.1
|
1.0
|
C
|
B:ASN33
|
4.7
|
15.1
|
1.0
|
CE1
|
B:TYR32
|
5.0
|
25.7
|
1.0
|
|
Chlorine binding site 4 out
of 4 in 8gz6
Go back to
Chlorine Binding Sites List in 8gz6
Chlorine binding site 4 out
of 4 in the Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain
Mono view
Stereo pair view
|
A full contact list of Chlorine with other atoms in the Cl binding
site number 4 of Crystal Structure of Neutralizing Vhh P17 in Complex with Sars-Cov-2 Alpha Variant Spike Receptor-Binding Domain within 5.0Å range:
probe
|
atom
|
residue
|
distance (Å)
|
B
|
Occ
|
B:Cl502
b:19.9
occ:1.00
|
N
|
B:ARG45
|
3.2
|
17.9
|
0.6
|
N
|
B:ARG45
|
3.2
|
18.8
|
0.4
|
O
|
B:HOH718
|
3.2
|
38.9
|
1.0
|
NH1
|
B:ARG105
|
3.2
|
18.2
|
1.0
|
NH1
|
B:ARG45
|
3.5
|
18.8
|
0.4
|
CB
|
B:ARG45
|
3.7
|
18.2
|
0.4
|
CB
|
B:ARG45
|
3.7
|
16.7
|
0.6
|
CG
|
B:ARG45
|
3.7
|
17.4
|
0.6
|
CD
|
B:ARG45
|
3.8
|
20.2
|
0.4
|
CG
|
B:ARG45
|
3.8
|
19.7
|
0.4
|
CD
|
B:ARG105
|
3.8
|
17.0
|
1.0
|
CA
|
B:GLU44
|
3.9
|
20.9
|
1.0
|
C
|
B:GLU44
|
4.0
|
20.2
|
1.0
|
CA
|
B:ARG45
|
4.0
|
17.0
|
0.6
|
CA
|
B:ARG45
|
4.1
|
18.1
|
0.4
|
CD
|
B:ARG45
|
4.1
|
18.5
|
0.6
|
CB
|
B:GLU44
|
4.1
|
23.1
|
1.0
|
NE2
|
B:GLN39
|
4.1
|
20.5
|
1.0
|
CZ
|
B:ARG105
|
4.3
|
17.6
|
1.0
|
NE
|
B:ARG45
|
4.5
|
18.4
|
0.6
|
CZ
|
B:ARG45
|
4.5
|
19.1
|
0.4
|
NE
|
B:ARG105
|
4.5
|
17.0
|
1.0
|
O
|
B:HOH651
|
4.6
|
61.1
|
1.0
|
NE
|
B:ARG45
|
4.6
|
19.1
|
0.4
|
O
|
B:ARG45
|
4.7
|
22.4
|
0.6
|
O
|
B:ARG45
|
4.8
|
20.5
|
0.4
|
CG
|
B:GLU44
|
4.8
|
30.6
|
1.0
|
C
|
B:ARG45
|
4.9
|
18.8
|
0.6
|
CD
|
B:GLN39
|
5.0
|
18.7
|
1.0
|
C
|
B:ARG45
|
5.0
|
18.5
|
0.4
|
|
Reference:
K.Yamaguchi,
I.Anzai,
R.Maeda,
M.Moriguchi,
T.Watanabe,
A.Imura,
A.Takaori-Kondo,
T.Inoue.
Structural Insights Into the Rational Design of A Nanobody That Binds with High Affinity to the Sars-Cov-2 Spike Variant. J.Biochem. 2022.
ISSN: ISSN 0021-924X
PubMed: 36413757
DOI: 10.1093/JB/MVAC096
Page generated: Tue Jul 30 10:11:52 2024
|